ANAB
Price
$22.14
Change
+$1.19 (+5.68%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
586.03M
48 days until earnings call
ENTA
Price
$7.81
Change
+$0.64 (+8.93%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
153.28M
54 days until earnings call
Interact to see
Advertisement

ANAB vs ENTA

Header iconANAB vs ENTA Comparison
Open Charts ANAB vs ENTABanner chart's image
AnaptysBio
Price$22.14
Change+$1.19 (+5.68%)
Volume$9.47K
Capitalization586.03M
Enanta Pharmaceuticals
Price$7.81
Change+$0.64 (+8.93%)
Volume$2.46K
Capitalization153.28M
ANAB vs ENTA Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. ENTA commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Buy and ENTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (ANAB: $20.95 vs. ENTA: $7.17)
Brand notoriety: ANAB and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 69% vs. ENTA: 107%
Market capitalization -- ANAB: $586.03M vs. ENTA: $153.28M
ANAB [@Biotechnology] is valued at $586.03M. ENTA’s [@Biotechnology] market capitalization is $153.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTA is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 4 TA indicator(s) are bullish while ENTA’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 4 bullish, 4 bearish.
  • ENTA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than ENTA.

Price Growth

ANAB (@Biotechnology) experienced а +7.99% price change this week, while ENTA (@Biotechnology) price change was -3.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 11, 2025.

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($586M) has a higher market cap than ENTA($153M). ANAB YTD gains are higher at: 58.233 vs. ENTA (24.696). ANAB has higher annual earnings (EBITDA): -59.63M vs. ENTA (-82.41M). ANAB has more cash in the bank: 266M vs. ENTA (204M). ANAB has less debt than ENTA: ANAB (15.1M) vs ENTA (58M). ANAB has higher revenues than ENTA: ANAB (123M) vs ENTA (64.8M).
ANABENTAANAB / ENTA
Capitalization586M153M383%
EBITDA-59.63M-82.41M72%
Gain YTD58.23324.696236%
P/E RatioN/AN/A-
Revenue123M64.8M190%
Total Cash266M204M130%
Total Debt15.1M58M26%
FUNDAMENTALS RATINGS
ANAB vs ENTA: Fundamental Ratings
ANAB
ENTA
OUTLOOK RATING
1..100
1061
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
87100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
701
SEASONALITY SCORE
1..100
4350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANAB's Valuation (84) in the Biotechnology industry is in the same range as ENTA (95). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ANAB's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as ENTA (100). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as ANAB (100). This means that ENTA’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's Price Growth Rating (60) in the Biotechnology industry is in the same range as ENTA (61). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ANAB (70). This means that ENTA’s stock grew significantly faster than ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABENTA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 9 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
59%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LTFOX21.090.05
+0.23%
Lord Abbett Affiliated F3
CUSRX14.55N/A
N/A
Cullen Small Cap Value Retail
MSAAX20.73N/A
N/A
Morgan Stanley Inst Passport ovrs eq C
CLSYX22.25-0.02
-0.09%
Columbia International Div Inc Inst3
AGRCX11.38-0.09
-0.78%
AB Growth C

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with QTTB. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
-2.10%
QTTB - ANAB
39%
Loosely correlated
-3.21%
ADCT - ANAB
37%
Loosely correlated
-2.87%
NRIX - ANAB
37%
Loosely correlated
-2.25%
SPRY - ANAB
36%
Loosely correlated
+1.53%
HRMY - ANAB
35%
Loosely correlated
-1.08%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with VRDN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-6.88%
VRDN - ENTA
37%
Loosely correlated
+0.05%
ADCT - ENTA
35%
Loosely correlated
-2.87%
ANAB - ENTA
35%
Loosely correlated
-2.10%
AKRO - ENTA
34%
Loosely correlated
+3.08%
FATE - ENTA
34%
Loosely correlated
-3.95%
More